Altheos, Inc. Names Barbara Wirostko, M.D., Chief Medical Officer

Published: Sep 30, 2010

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Altheos, Inc., a biopharmaceutical company focused on next generation treatments for glaucoma and ocular hypertension, announced today that Barbara Wirostko, M.D., has been appointed Chief Medical Officer. Dr. Wirostko is a board certified ophthalmologist with glaucoma subspecialty training. Prior to joining Altheos, she was senior medical director and the glaucoma medical team lead at Pfizer where she was responsible for pipeline strategy in glaucoma, overseeing the pediatric development program and Global Medical Affairs Programs for the Xalabrands franchise. Prior to joining Pfizer, she was chief ophthalmologist specializing in glaucoma at the Huntington Medical Group PC in Huntington, NY. During her 10 years in practice, she was a clinical investigator for a number of pivotal glaucoma clinical trials.

Back to news